Work

Gene actionability according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) in No Specific Molecular Profile (NSMP) endometrial cancer

Year: 2025

Type: article

Abstract: BACKGROUND: The No Specific Molecular Profile (NSMP) subtype accounts for ∼30%-40% of endometrial cancer (EC), comprising a heterogeneous group of EC. PATIENTS AND METHODS: The primary outcome of this study was the prevalence of actionable genomic alterations in NSMP EC, classified according to the European Society for Medical Oncology (ESMO) Scale for Clinical Actionability of molecular Targets (ESCAT). Oncogenic and likely oncogenic alterations, pathways, and co-mutation patterns were reported. The analysis was stratified by risk group according to the European Society of Gynaecological Oncology (ESGO)-ESMO-European SocieTy for Radiotherapy and Oncology (ESTRO) guidelines. Patients with NSMP EC enrolled in the FPG500 comprehensive cancer genome profiling program (NCT06020625) were included. RESULTS: ) and PTEN with PIK3R1 (OR = 4.36, P value = 0.009). An alteration in the phosphatidylinositol-3 kinase (PI3K) pathway was found in 94% of patients in the overall population and in 98% of patients with an ESCAT tier I-III alteration. CONCLUSION: Our findings highlight potentially actionable alterations in NSMP EC patients, supporting the exploration of tailored molecular-matched therapies according to risk groups.

Source: ESMO Open

DOI: 10.1016/j.esmoop.2025.105755